Please assess the completion status of the following clinical trial:

Trial Title: Re³ (Re-Cube: Retain Remicade® Response)(Study P04249AM3)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* aged 18 years or more~* with RA according to ACR criteria~* presented with a disease flare after initial response to infliximab, with both response and flare being defined using the DAS28 score (EULAR criteria)~* received the standard Remicade® dosing schedule per the EU label (3 mg/kg at Weeks 0, 2, 6, \[and 14\])~* an initial response documented by moderate or good DAS28 improvement (EULAR criteria) from Week 0 to Week 6 or 14.~Exclusion Criteria:~* a female who is, or intends to become, pregnant during or within 6 months of the end of the study, is nursing or not using adequate contraceptive measures~* has not observed the designated periods for concomitant medications~* used any investigational medical product within 30 days prior to Baseline~* any clinically significant deviation from normal in the physical examination or chest X-ray that in the investigator's judgment, may interfere with the study evaluation or affect subject safety~* rheumatic disease other than RA or has any systemic inflammatory condition with signs and symptoms that might confound the evaluations of safety and toxicity~* allergic reaction/sensitivity to the study drug or its excipients that requires corticosteroid pre-infusion medication.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Increased Frequency (Type: EXPERIMENTAL): Continuing the same dose of 3 mg/kg infliximab, but at every 6 weeks
- Increased Dose (Type: EXPERIMENTAL): 3 mg/kg infliximab + 1 extra vial (100 mg) infliximab, every 8 weeks
- Control (Type: ACTIVE_COMPARATOR): Continuation of infliximab 3 mg/kg every 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).